Chiratae Ventures, India’s leading Venture Capital fund, on Friday announced their seed investment in WeInnovate Biosolutions, as a part of their DeepTech Innovators Programme 6th Cohort.
According to the company statement, the startup will be using the fresh funding for product approvals, sales, and marketing.
Founded in 2016 by three friends — Dr Milind Choudhari, Dr Prasad Bhagat, and Dr Anupama Engineer, Weinnovate Biosolutions has developed antimicrobial solutions that reduce hospital-acquired infections and is helping save millions on hospitalization bills.
“With the current steep rise in hospital-acquired infections (HAI), followed by the indiscriminate use of antibiotics, it was important to come up with a solution that would drastically bring down the incidences of HAI. This would ultimately result in reduced hospitalisation stay, improve hospital foot-fall, and improve the quality of stay for a patient in any hospital”, said Dr Milind Choudhari, Founder and CEO of WeInnovate Biosolutions.
According to the World Health Organization, over 1.4 million people across the globe suffer from hospital-acquired infections (HAI) at any given time. Weinnovate Biosolutions is the first-ever, “Made in India” technology catering to holistic improvement in the Indian hospitalisation scenario. This “completely Indian solution” not only pushes India towards its “Aatmanirbhar Bharat” mission but will also attract medical tourism.
South Africa Today